Literature DB >> 33442415

Cytochalasin H isolated from mangrove-derived endophytic fungus inhibits epithelial-mesenchymal transition and cancer stemness via YAP/TAZ signaling pathway in non-small cell lung cancer cells.

Zihan Xiu1, Jiao Liu1, Xin Wu2,3, Xiangyong Li1, Sanzhong Li1, Xiaofeng Wu1, Xiaohua Lv2, Hua Ye2,3, Xudong Tang1,2,3,4.   

Abstract

Our previous studies have isolated cytochalasin H (CyH) from endophytic fungus derived from mangrove and found that CyH induced apoptosis and inhibited migration and angiogenesis in non-small cell lung cancer (NSCLC) cells. In this study, we further investigated the effect of CyH on epithelial-mesenchymal transition (EMT) and cancer stemness of A549 and NCI-H460 NSCLC cells and the underlying mechanisms, especially the role of YAP/ TAZ signaling pathway in the process. Our results showed that CyH significantly inhibited invasive ability and the sphere formation of NSCLC cells. The expression of E-cadherin, an EMT epithelial marker, was obviously up-regulated, while the expression of Vimentin and N-cadherin, the EMT mesenchymal markers, was dramatically down-regulated by CyH treatment in NSCLC cells. Moreover, the expression of EMT-associated transcription factors including Slug, Twist1, and Snail1 and stemness markers including Nanog, Sox-2, and Oct-4 was significantly down-regulated by CyH treatment in NSCLC cells. Additionally, CyH significantly down-regulated YAP and TAZ expression and up-regulated LAST1/2 and MST1/2 expression, and CyH inhibited the interaction between YAP and TEAD. Furthermore, YAP knockdown abolished the effect of CyH on the expression of EMT- and stemness-related markers in NSCLC cells. Taken together, these results suggest that CyH inhibits EMT and cancer stemness of NSCLC cells via the regulation of YAP/TAZ signaling pathway. © The author(s).

Entities:  

Keywords:  YAP/TAZ; cancer stemness; cytochalasin H (CyH); epithelial-mesenchymal transition (EMT); mangrove; non-small cell lung cancer (NSCLC)

Year:  2021        PMID: 33442415      PMCID: PMC7797655          DOI: 10.7150/jca.50512

Source DB:  PubMed          Journal:  J Cancer        ISSN: 1837-9664            Impact factor:   4.207


  40 in total

1.  YAP promotes epithelial mesenchymal transition by upregulating Slug expression in human colorectal cancer cells.

Authors:  Dan Cheng; Lan Jin; Yunhe Chen; Xueyan Xi; Yang Guo
Journal:  Int J Clin Exp Pathol       Date:  2020-04-01

Review 2.  Anticancer compounds derived from fungal endophytes: their importance and future challenges.

Authors:  Ravindra N Kharwar; Ashish Mishra; Surendra K Gond; Andrea Stierle; Donald Stierle
Journal:  Nat Prod Rep       Date:  2011-04-01       Impact factor: 13.423

3.  Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases.

Authors:  Romano Demicheli; Marco Fornili; Federico Ambrogi; Kristin Higgins; Jessamy A Boyd; Elia Biganzoli; Chris R Kelsey
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

4.  Hippo coactivator YAP1 upregulates SOX9 and endows esophageal cancer cells with stem-like properties.

Authors:  Shumei Song; Jaffer A Ajani; Soichiro Honjo; Dipen M Maru; Qiongrong Chen; Ailing W Scott; Todd R Heallen; Lianchun Xiao; Wayne L Hofstetter; Brian Weston; Jeffrey H Lee; Roopma Wadhwa; Kazuki Sudo; John R Stroehlein; James F Martin; Mien-Chie Hung; Randy L Johnson
Journal:  Cancer Res       Date:  2014-06-06       Impact factor: 12.701

Review 5.  The Hippo Pathway and YAP/TAZ-TEAD Protein-Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment.

Authors:  Matteo Santucci; Tatiana Vignudelli; Stefania Ferrari; Marco Mor; Laura Scalvini; Maria Laura Bolognesi; Elisa Uliassi; Maria Paola Costi
Journal:  J Med Chem       Date:  2015-03-11       Impact factor: 7.446

Review 6.  Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.

Authors:  James J Crawford; Sarah M Bronner; Jason R Zbieg
Journal:  Expert Opin Ther Pat       Date:  2018-12-02       Impact factor: 6.674

7.  The epithelial-mesenchymal transition generates cells with properties of stem cells.

Authors:  Sendurai A Mani; Wenjun Guo; Mai-Jing Liao; Elinor Ng Eaton; Ayyakkannu Ayyanan; Alicia Y Zhou; Mary Brooks; Ferenc Reinhard; Cheng Cheng Zhang; Michail Shipitsin; Lauren L Campbell; Kornelia Polyak; Cathrin Brisken; Jing Yang; Robert A Weinberg
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

8.  TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells.

Authors:  M Bartucci; R Dattilo; C Moriconi; A Pagliuca; M Mottolese; G Federici; A Di Benedetto; M Todaro; G Stassi; F Sperati; M I Amabile; E Pilozzi; M Patrizii; M Biffoni; M Maugeri-Saccà; S Piccolo; R De Maria
Journal:  Oncogene       Date:  2014-02-17       Impact factor: 9.867

Review 9.  The Role of Hippo Pathway in Cancer Stem Cell Biology.

Authors:  Jae Hyung Park; Ji Eun Shin; Hyun Woo Park
Journal:  Mol Cells       Date:  2018-02-05       Impact factor: 5.034

10.  Overexpression of Human Papillomavirus Type 16 Oncoproteins Enhances Epithelial-Mesenchymal Transition via STAT3 Signaling Pathway in Non-Small Cell Lung Cancer Cells.

Authors:  Wenzhang Zhang; Xin Wu; Liang Hu; Yuefan Ma; Zihan Xiu; Bingyu Huang; Yun Feng; Xudong Tang
Journal:  Oncol Res       Date:  2016-12-15       Impact factor: 5.574

View more
  2 in total

1.  A Novel Tumor Suppressor Gene, ZNF24, Inhibits the Development of NSCLC by Inhibiting the WNT Signaling Pathway to Induce Cell Senescence.

Authors:  Bo Pang; Yong Wang; Xiaoyan Chang
Journal:  Front Oncol       Date:  2021-07-27       Impact factor: 5.738

2.  Integrative bioinformatics and experimental analysis revealed TEAD as novel prognostic target for hepatocellular carcinoma and its roles in ferroptosis regulation.

Authors:  Xinxin Ren; Xiang Wang; Yuanliang Yan; Xi Chen; Yuan Cai; Qiuju Liang; Bi Peng; Zhijie Xu; Qingchun He; Fanhua Kang; Jianbo Li; Wenqin Zhang; Qianhui Hong; Jinwu Peng; Muzhang Xiao
Journal:  Aging (Albany NY)       Date:  2022-01-25       Impact factor: 5.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.